Viewing Study NCT00463034


Ignite Creation Date: 2025-12-25 @ 2:28 AM
Ignite Modification Date: 2025-12-30 @ 1:46 PM
Study NCT ID: NCT00463034
Status: UNKNOWN
Last Update Posted: 2013-12-18
First Post: 2007-04-18
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Genes That Affect Disease Progression in Women With Newly Diagnosed or Metastatic Breast Cancer
Sponsor: University of Sheffield
Organization:

Study Overview

Official Title: Genetic Factors Affecting Breast Cancer Progression
Status: UNKNOWN
Status Verified Date: 2008-11
Last Known Status: ACTIVE_NOT_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: RATIONALE: Studying samples of blood and tumor tissue in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and help doctors understand how patients respond to treatment.

PURPOSE: This clinical trial is assessing how changes in genes affect disease progression in women with newly diagnosed or metastatic breast cancer.
Detailed Description: OBJECTIVES:

Primary

* Correlate inherited and acquired variations in candidate genes with breast cancer progression and survival in women with newly diagnosed or metastatic breast cancer.

Secondary

* Establish a repository of blood and tumor samples from these patients, linked to a database of clinical, pathological, and treatment outcome data for future research studies.

OUTLINE: Patients complete epidemiological questionnaires and undergo blood sample collection. Tumor tissue specimens are requested from the pathology departments.

Blood samples are analyzed for single nucleotide polymorphisms and other polymorphic variants in candidate genes by polymerase chain reaction. Candidate genes include genes involved in the DNA damage response, programed cell death, inflammation, and angiogenesis. Tumor samples are analyzed by tissue microarrays using immunohistochemistry, denaturing high-performance liquid chromatography, and DNA sequencing to study genetic changes in the tumor.

PROJECTED ACCRUAL: A total of 1,800 patients will be accrued for this study.

Study Oversight

Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
SHEFF-05/Q2308/15 None None View
SHEFF-USMS-05/Q2308/15 None None View
EU-20726 None None View
SHEFF-STH13824 None None View
SHEFF-106364 None None View
GENFABRCA None None View